In the past week, DMAC stock has gone down by -4.29%, with a monthly decline of -13.14% and a quarterly plunge of -5.80%. The volatility ratio for the week is 8.49%, and the volatility levels for the last 30 days are 7.57% for DiaMedica Therapeutics Inc The simple moving average for the past 20 days is -7.62% for DMAC’s stock, with a -24.44% simple moving average for the past 200 days.
Is It Worth Investing in DiaMedica Therapeutics Inc (NASDAQ: DMAC) Right Now?
Company’s 36-month beta value is 1.17.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DMAC is 24.15M, and currently, short sellers hold a 5.11% ratio of that floaft. The average trading volume of DMAC on July 02, 2025 was 158.63K shares.
DMAC) stock’s latest price update
DiaMedica Therapeutics Inc (NASDAQ: DMAC)’s stock price has dropped by -8.46 in relation to previous closing price of 3.9. Nevertheless, the company has seen a loss of -4.29% in its stock price over the last five trading days. businesswire.com reported 2025-06-24 that MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investa.
Analysts’ Opinion of DMAC
Many brokerage firms have already submitted their reports for DMAC stocks, with H.C. Wainwright repeating the rating for DMAC by listing it as a “Buy.” The predicted price for DMAC in the upcoming period, according to H.C. Wainwright is $7 based on the research report published on October 07, 2024 of the previous year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see DMAC reach a price target of $8. The rating they have provided for DMAC stocks is “Buy” according to the report published on April 24th, 2024.
Oppenheimer gave a rating of “Outperform” to DMAC, setting the target price at $7 in the report published on June 22nd of the previous year.
DMAC Trading at -10.23% from the 50-Day Moving Average
After a stumble in the market that brought DMAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.64% of loss for the given period.
Stock Fundamentals for DMAC
The total capital return value is set at -0.85. Equity return is now at value -67.25, with -61.30 for asset returns.
Based on DiaMedica Therapeutics Inc (DMAC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -71.43.
Currently, EBITDA for the company is -24.38 million with net debt to EBITDA at 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.02.
Conclusion
In a nutshell, DiaMedica Therapeutics Inc (DMAC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
